Cover Image
市場調查報告書

肝癌:開發中產品分析

Hepatocellular Carcinoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229736
出版日期 內容資訊 英文 960 Pages
訂單完成後即時交付
價格
Back to Top
肝癌:開發中產品分析 Hepatocellular Carcinoma - Pipeline Review, H2 2016
出版日期: 2016年11月30日 內容資訊: 英文 960 Pages
簡介

肝細胞癌(HCC)是有女性比男性更容易罹患這個趨勢的癌症,其症狀有腹部(尤其是右上部)的疼痛、容易長出痣、容易出血、腹部膨脹感、黃膽等。罹患肝細胞癌的主要原因有大量攝取酒精、肝臟自體的兔疫疾病、B型或C型肝炎病毒的感染、長期(慢性)的肝臟發炎、體內積蓄過多鐵質(血色素沉著病)等。

本報告提供肝癌治療藥的開發中產品概要和臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

肝癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

肝癌:企業開發中的治療藥

肝癌:大學/機關研究中的治療藥

肝癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

肝癌:企業開發中的產品

肝癌:大學/機關研究中的產品

肝癌的治療藥的開發企業

肝癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

肝癌:最近的開發平台趨勢

肝癌:暫停中的計劃

肝癌:開發中止的產品

肝癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8748IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2016, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.

Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 16, 69, 42, 4, 62 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 8, 4, 1, 21 and 2 molecules, respectively.Hepatocellular Carcinoma.

Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 8
  • Hepatocellular Carcinoma Overview 9
  • Therapeutics Development 10
  • Hepatocellular Carcinoma - Therapeutics under Development by Companies 12
  • Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes 22
  • Hepatocellular Carcinoma - Pipeline Products Glance 24
  • Hepatocellular Carcinoma - Products under Development by Companies 27
  • Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes 42
  • Hepatocellular Carcinoma - Companies Involved in Therapeutics Development 44
  • Hepatocellular Carcinoma - Therapeutics Assessment 178
  • Drug Profiles 206
  • Hepatocellular Carcinoma - Dormant Projects 900
  • Hepatocellular Carcinoma - Discontinued Products 911
  • Hepatocellular Carcinoma - Product Development Milestones 915
  • Appendix 933

List of Tables

  • Number of Products under Development for Hepatocellular Carcinoma, H2 2016 36
  • Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H2 2016 37
  • Number of Products under Development by Companies, H2 2016 38
  • Number of Products under Development by Companies, H2 2016 (Contd..1) 39
  • Number of Products under Development by Companies, H2 2016 (Contd..2) 40
  • Number of Products under Development by Companies, H2 2016 (Contd..3) 41
  • Number of Products under Development by Companies, H2 2016 (Contd..4) 42
  • Number of Products under Development by Companies, H2 2016 (Contd..5) 43
  • Number of Products under Development by Companies, H2 2016 (Contd..6) 44
  • Number of Products under Development by Companies, H2 2016 (Contd..7) 45
  • Number of Products under Development by Companies, H2 2016 (Contd..8) 46
  • Number of Products under Development by Companies, H2 2016 (Contd..9) 47
  • Number of Products under Investigation by Universities/Institutes, H2 2016 48
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 49
  • Comparative Analysis by Late Stage Development, H2 2016 50
  • Comparative Analysis by Clinical Stage Development, H2 2016 51
  • Comparative Analysis by Early Stage Development, H2 2016 52
  • Products under Development by Companies, H2 2016 53
  • Products under Development by Companies, H2 2016 (Contd..1) 54
  • Products under Development by Companies, H2 2016 (Contd..2) 55
  • Products under Development by Companies, H2 2016 (Contd..3) 56
  • Products under Development by Companies, H2 2016 (Contd..4) 57
  • Products under Development by Companies, H2 2016 (Contd..5) 58
  • Products under Development by Companies, H2 2016 (Contd..6) 59
  • Products under Development by Companies, H2 2016 (Contd..7) 60
  • Products under Development by Companies, H2 2016 (Contd..8) 61
  • Products under Development by Companies, H2 2016 (Contd..9) 62
  • Products under Development by Companies, H2 2016 (Contd..10) 63
  • Products under Development by Companies, H2 2016 (Contd..11) 64
  • Products under Development by Companies, H2 2016 (Contd..12) 65
  • Products under Development by Companies, H2 2016 (Contd..13) 66
  • Products under Development by Companies, H2 2016 (Contd..14) 67
  • Products under Investigation by Universities/Institutes, H2 2016 68
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 69
  • Hepatocellular Carcinoma - Pipeline by 4SC AG, H2 2016 70
  • Hepatocellular Carcinoma - Pipeline by AB Science SA, H2 2016 71
  • Hepatocellular Carcinoma - Pipeline by Acceleron Pharma Inc, H2 2016 72
  • Hepatocellular Carcinoma - Pipeline by ACROVIS Pharma AG, H2 2016 73
  • Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 74
  • Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H2 2016 75
  • Hepatocellular Carcinoma - Pipeline by Alfact Innovation, H2 2016 76
  • Hepatocellular Carcinoma - Pipeline by Amgen Inc, H2 2016 77
  • Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H2 2016 78
  • Hepatocellular Carcinoma - Pipeline by ArQule Inc, H2 2016 79
  • Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H2 2016 80
  • Hepatocellular Carcinoma - Pipeline by Astellas Pharma Inc, H2 2016 81
  • Hepatocellular Carcinoma - Pipeline by Astex Pharmaceuticals Inc, H2 2016 82
  • Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H2 2016 83
  • Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 84
  • Hepatocellular Carcinoma - Pipeline by Bayer AG, H2 2016 85
  • Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H2 2016 86
  • Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 87
  • Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H2 2016 88
  • Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H2 2016 89
  • Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 90
  • Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H2 2016 91
  • Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 92
  • Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H2 2016 93
  • Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H2 2016 94
  • Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H2 2016 95
  • Hepatocellular Carcinoma - Pipeline by Celgene Corp, H2 2016 96
  • Hepatocellular Carcinoma - Pipeline by Celldex Therapeutics Inc, H2 2016 97
  • Hepatocellular Carcinoma - Pipeline by Celsion Corp, H2 2016 98
  • Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H2 2016 99
  • Hepatocellular Carcinoma - Pipeline by Chroma Therapeutics Ltd, H2 2016 100
  • Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 101
  • Hepatocellular Carcinoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 102
  • Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H2 2016 103
  • Hepatocellular Carcinoma - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 104
  • Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H2 2016 105
  • Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H2 2016 106
  • Hepatocellular Carcinoma - Pipeline by Eli Lilly and Company, H2 2016 107
  • Hepatocellular Carcinoma - Pipeline by Endocyte Inc, H2 2016 108
  • Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H2 2016 109
  • Hepatocellular Carcinoma - Pipeline by eTheRNA Immunotherapies NV, H2 2016 110
  • Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H2 2016 111
  • Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 112
  • Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H2 2016 113
  • Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H2 2016 114
  • Hepatocellular Carcinoma - Pipeline by Genelux Corp, H2 2016 115
  • Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H2 2016 116
  • Hepatocellular Carcinoma - Pipeline by Genosco, H2 2016 117
  • Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H2 2016 118
  • Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2016 119
  • Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H2 2016 120
  • Hepatocellular Carcinoma - Pipeline by Green Cross Cell Corp, H2 2016 121
  • Hepatocellular Carcinoma - Pipeline by Green Cross Corp, H2 2016 122
  • Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H2 2016 123
  • Hepatocellular Carcinoma - Pipeline by HanAll Biopharma Co Ltd, H2 2016 124
  • Hepatocellular Carcinoma - Pipeline by HEC Pharm Co., Ltd., H2 2016 125
  • Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H2 2016 126
  • Hepatocellular Carcinoma - Pipeline by Immune Therapeutics, Inc., H2 2016 127
  • Hepatocellular Carcinoma - Pipeline by Immunicum AB, H2 2016 128
  • Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H2 2016 129
  • Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H2 2016 130
  • Hepatocellular Carcinoma - Pipeline by Immunovative Therapies Ltd, H2 2016 131
  • Hepatocellular Carcinoma - Pipeline by In-Cell-Art SAS, H2 2016 132
  • Hepatocellular Carcinoma - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 133
  • Hepatocellular Carcinoma - Pipeline by Inspyr Therapeutics Inc, H2 2016 134
  • Hepatocellular Carcinoma - Pipeline by InteRNA Technologies BV, H2 2016 135
  • Hepatocellular Carcinoma - Pipeline by Jenrin Discovery Inc, H2 2016 136
  • Hepatocellular Carcinoma - Pipeline by Johnson & Johnson, H2 2016 137
  • Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd, H2 2016 138
  • Hepatocellular Carcinoma - Pipeline by Karcinolys SAS, H2 2016 139
  • Hepatocellular Carcinoma - Pipeline by Kite Pharma Inc, H2 2016 140
  • Hepatocellular Carcinoma - Pipeline by Komipharm International Co Ltd, H2 2016 141
  • Hepatocellular Carcinoma - Pipeline by Kowa Company Ltd, H2 2016 142
  • Hepatocellular Carcinoma - Pipeline by Les Laboratoires Servier SAS, H2 2016 143
  • Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals Inc, H2 2016 144
  • Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 145
  • Hepatocellular Carcinoma - Pipeline by MaxCyte Inc, H2 2016 146
  • Hepatocellular Carcinoma - Pipeline by MedImmune LLC, H2 2016 147
  • Hepatocellular Carcinoma - Pipeline by Medivation Inc, H2 2016 148
  • Hepatocellular Carcinoma - Pipeline by Medivir AB, H2 2016 149
  • Hepatocellular Carcinoma - Pipeline by Merck & Co Inc, H2 2016 150
  • Hepatocellular Carcinoma - Pipeline by Merck KGaA, H2 2016 151
  • Hepatocellular Carcinoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 152
  • Hepatocellular Carcinoma - Pipeline by Midatech Pharma Plc, H2 2016 153
  • Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 154
  • Hepatocellular Carcinoma - Pipeline by Mina Therapeutics Ltd, H2 2016 155
  • Hepatocellular Carcinoma - Pipeline by Molecular Partners AG, H2 2016 156
  • Hepatocellular Carcinoma - Pipeline by MolMed SpA, H2 2016 157
  • Hepatocellular Carcinoma - Pipeline by MultiCell Technologies Inc, H2 2016 158
  • Hepatocellular Carcinoma - Pipeline by NormOxys Inc, H2 2016 159
  • Hepatocellular Carcinoma - Pipeline by Novartis AG, H2 2016 160
  • Hepatocellular Carcinoma - Pipeline by NovaTarg Therapeutics Inc, H2 2016 161
  • Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corp, H2 2016 162
  • Hepatocellular Carcinoma - Pipeline by Omeros Corp, H2 2016 163
  • Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc, H2 2016 164
  • Hepatocellular Carcinoma - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 165
  • Hepatocellular Carcinoma - Pipeline by OncoTherapy Science Inc, H2 2016 166
  • Hepatocellular Carcinoma - Pipeline by Oneness Biotech Co Ltd, H2 2016 167
  • Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 168
  • Hepatocellular Carcinoma - Pipeline by Onxeo SA, H2 2016 169
  • Hepatocellular Carcinoma - Pipeline by Otsuka Holdings Co Ltd, H2 2016 170
  • Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 171
  • Hepatocellular Carcinoma - Pipeline by PepVax Inc, H2 2016 172
  • Hepatocellular Carcinoma - Pipeline by Pfizer Inc, H2 2016 173
  • Hepatocellular Carcinoma - Pipeline by Pharma Mar SA, H2 2016 174
  • Hepatocellular Carcinoma - Pipeline by PharmAbcine Inc, H2 2016 175
  • Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corp, H2 2016 176
  • Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH, H2 2016 177
  • Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016 178
  • Hepatocellular Carcinoma - Pipeline by RedHill Biopharma Ltd, H2 2016 179
  • Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc, H2 2016 180
  • Hepatocellular Carcinoma - Pipeline by Rigontec GmbH, H2 2016 181
  • Hepatocellular Carcinoma - Pipeline by Saronic Biotechnology Inc, H2 2016 182
  • Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd, H2 2016 183
  • Hepatocellular Carcinoma - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016 184
  • Hepatocellular Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2016 185
  • Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company Ltd, H2 2016 186
  • Hepatocellular Carcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 187
  • Hepatocellular Carcinoma - Pipeline by TC BioPharm Ltd, H2 2016 188
  • Hepatocellular Carcinoma - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 189
  • Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc, H2 2016 190
  • Hepatocellular Carcinoma - Pipeline by Theravectys SA, H2 2016 191
  • Hepatocellular Carcinoma - Pipeline by Threshold Pharmaceuticals Inc, H2 2016 192
  • Hepatocellular Carcinoma - Pipeline by Tiziana Life Sciences Plc, H2 2016 193
  • Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 194
  • Hepatocellular Carcinoma - Pipeline by Tumorend LLC, H2 2016 195
  • Hepatocellular Carcinoma - Pipeline by UbiVac LLC, H2 2016 196
  • Hepatocellular Carcinoma - Pipeline by VasGene Therapeutics Inc, H2 2016 197
  • Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H2 2016 198
  • Hepatocellular Carcinoma - Pipeline by Vect-Horus SAS, H2 2016 199
  • Hepatocellular Carcinoma - Pipeline by Verlyx Pharma Inc, H2 2016 200
  • Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics LLC, H2 2016 201
  • Hepatocellular Carcinoma - Pipeline by Virttu Biologics Ltd, H2 2016 202
  • Hepatocellular Carcinoma - Pipeline by Vyriad Inc, H2 2016 203
  • Assessment by Monotherapy Products, H2 2016 204
  • Assessment by Combination Products, H2 2016 205
  • Number of Products by Stage and Target, H2 2016 207
  • Number of Products by Stage and Mechanism of Action, H2 2016 218
  • Number of Products by Stage and Route of Administration, H2 2016 229
  • Number of Products by Stage and Molecule Type, H2 2016 231
  • Hepatocellular Carcinoma - Dormant Projects, H2 2016 926
  • Hepatocellular Carcinoma - Dormant Projects (Contd..1), H2 2016 927
  • Hepatocellular Carcinoma - Dormant Projects (Contd..2), H2 2016 928
  • Hepatocellular Carcinoma - Dormant Projects (Contd..3), H2 2016 929
  • Hepatocellular Carcinoma - Dormant Projects (Contd..4), H2 2016 930
  • Hepatocellular Carcinoma - Dormant Projects (Contd..5), H2 2016 931
  • Hepatocellular Carcinoma - Dormant Projects (Contd..6), H2 2016 932
  • Hepatocellular Carcinoma - Dormant Projects (Contd..7), H2 2016 933
  • Hepatocellular Carcinoma - Dormant Projects (Contd..8), H2 2016 934
  • Hepatocellular Carcinoma - Dormant Projects (Contd..9), H2 2016 935
  • Hepatocellular Carcinoma - Dormant Projects (Contd..10), H2 2016 936
  • Hepatocellular Carcinoma - Discontinued Products, H2 2016 937
  • Hepatocellular Carcinoma - Discontinued Products (Contd..1), H2 2016 938
  • Hepatocellular Carcinoma - Discontinued Products (Contd..2), H2 2016 939
  • Hepatocellular Carcinoma - Discontinued Products (Contd..3), H2 2016 940

List of Figures

  • Number of Products under Development for Hepatocellular Carcinoma, H2 2016 36
  • Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H2 2016 37
  • Number of Products under Development by Companies, H2 2016 38
  • Number of Products under Investigation by Universities/Institutes, H2 2016 48
  • Comparative Analysis by Late Stage Development, H2 2016 50
  • Comparative Analysis by Clinical Stage Development, H2 2016 51
  • Comparative Analysis by Early Stage Products, H2 2016 52
  • Assessment by Monotherapy Products, H2 2016 204
  • Assessment by Combination Products, H2 2016 205
  • Number of Products by Top 10 Targets, H2 2016 206
  • Number of Products by Stage and Top 10 Targets, H2 2016 206
  • Number of Products by Top 10 Mechanism of Actions, H2 2016 217
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 217
  • Number of Products by Top 10 Routes of Administration, H2 2016 228
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016 228
  • Number of Products by Top 10 Molecule Types, H2 2016 230
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016 230
Back to Top